Piraeus Medical, Inc. appears in FDA device records as the applicant for premarket notification K262277, covering a device named 70 NeuGlide Catheter. The filing lists product code QJP and regulation number 870.1250, the classification for a percutaneous neurovasculature catheter in Class II. The supplied portfolio snapshot contains one linked record, a 510(k) with a substantially equivalent decision, and the sample of that collection is the same single record. Those figures describe the supplied filings at the snapshot date, not company sales, total portfolio or safety performance. [1][2][3]

The K262277 filing and its scope

FDA records show K262277 received on July 6, 2026, with a decision date of September 4, 2026, decision code SESE and the description Substantially Equivalent. The record carries product code QJP, advisory committee CV, review advisory committee NE and a Special clearance type, with a summary listed as the statement or summary. The FDA determination letter is dated September 4, 2026, and names the trade device as 70 NeuGlide Catheter under regulation 21 CFR 870.1250, Class II, with product codes QJP and DQY. [1][2]

The determination letter states that, based on the results of bench performance testing, the subject and predicate devices are substantially equivalent. That statement describes the basis recorded in the letter; it is not a finding of clinical performance, and no clinical outcome data appear in the public documents. [2]

Documented catheter identities

A GUDID-derived record for primary DI 00860015527738 describes the 70 NeuGlide Catheter, model and catalog number 100898-002, as having an inner diameter of 0.070 inch (5F compatible), a maximum outer diameter of 0.084 inch (6F compatible) and a working length of 100 cm. The same record lists the device as sterile, single use, prescription-only, in commercial distribution, and states that labeling does not contain MRI safety information. [6]

Piraeus Medical's own instructions page lists the 87 NeuGlide Catheter, 87 NeuGlide+ Catheter, 93 NeuFlex Catheter and 70 NeuGlide Catheter, each with instructions for use covering indications, safety and precautions. The company homepage describes patented technology enabling a linerless catheter construction and presents the 87 NeuGlide+ at 0.087 inch inner diameter, compatible with a 7F introducer sheath, and the 93 NeuFlex at 0.093 inch inner diameter, compatible with an 8F introducer sheath. These are company-published descriptions. [4][5]

A separate FDA premarket notification, K240971, names the 87 NeuGlide Catheter with applicant Piraeus Medical, received April 9, 2024, decided December 6, 2024, substantially equivalent, under regulation 870.1250 with product codes QJP and DQY. It is a Traditional filing, not third-party reviewed, and not a combination product. [7]

Applicant identity and contact details

The K262277 record gives the applicant as Piraeus Medical, Inc., with a Maple Grove, Minnesota address and Sarah Kabanuk listed as contact; the determination letter addresses Sarah Kabanuk as COO at the same Maple Grove address. That address is a filing address and is not treated here as a verified headquarters. The company website publishes the same Maple Grove street address, a phone number and an email contact. [1][2][5]

No parent company, brand owner or corporate ownership structure is verified in the public documents, so the profile treats Piraeus Medical, Inc. only as the named FDA applicant. The K240971 record lists a different applicant contact and correspondent, which the sources do not reconcile with the K262277 contact. [1][2][7]